Induction of tolerance in mice by uricase and monomethoxypolyethylene glycol-modified uricase
- PMID: 6746105
- DOI: 10.1159/000233591
Induction of tolerance in mice by uricase and monomethoxypolyethylene glycol-modified uricase
Abstract
The ability to induce tolerance to uricase by the administration of native uricase, and uricase modified by the covalent attachment of monomethoxypolyethylene glycol (PEG) was examined. Uricase, and uricase with PEG attached to 35% (PEG-uricase 35%) and 70% (PEG-uricase 70%) of available amino groups were found to induce tolerance in mice not previously sensitized to uricase. There was a dampening of the IgG, IgE and IgM antibody response to uricase which persisted even after a second sensitizing dose of uricase was administered to these animals. PEG-uricases were found to have little or no immunogenicity when injected into mice and a reduced immunogenicity and antigenicity when tested in rabbits. Native uricase, however, was found to be immunogenic and antigenic in mice and rabbits. Mice sensitized to native uricase were injected with uricase, PEG-uricase 35% or 70% to induce tolerance. After a second sensitizing injection of uricase, circulating levels of IgE, IgG and IgM were measured. All three enzymes induced tolerance in the IgE class of antibody but there was no significant change in the hemagglutinating antibody levels of the mice. Mice injected with 1 mg of uricase died from anaphylaxis. PEG-uricase 35% was found to induce the most effective tolerance in both unsensitized and sensitized mice.
Similar articles
-
Studies on antigenicity of the polyethylene glycol (PEG)-modified uricase.Int J Immunopharmacol. 1985;7(5):725-30. doi: 10.1016/0192-0561(85)90158-4. Int J Immunopharmacol. 1985. PMID: 2412977
-
Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.Arthritis Res Ther. 2006;8(1):R12. doi: 10.1186/ar1861. Arthritis Res Ther. 2006. PMID: 16356199 Free PMC article. Clinical Trial.
-
Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma.Ann Intern Med. 1988 Jul 15;109(2):114-7. doi: 10.7326/0003-4819-109-2-114. Ann Intern Med. 1988. PMID: 3289428
-
Inhibition of the effector phase of IgE-mediated allergies by tolerogenic conjugates of allergens and monomethoxypolyethylene glycol.Int Arch Allergy Immunol. 1995 May-Jun;107(1-3):316-8. doi: 10.1159/000237012. Int Arch Allergy Immunol. 1995. PMID: 7613157 Review.
-
PEG-uricase in the management of treatment-resistant gout and hyperuricemia.Adv Drug Deliv Rev. 2008 Jan 3;60(1):59-68. doi: 10.1016/j.addr.2007.06.011. Epub 2007 Aug 14. Adv Drug Deliv Rev. 2008. PMID: 17826865 Review.
Cited by
-
Mucosal production of uric acid by airway epithelial cells contributes to particulate matter-induced allergic sensitization.Mucosal Immunol. 2016 May;9(3):809-20. doi: 10.1038/mi.2015.104. Epub 2015 Oct 28. Mucosal Immunol. 2016. PMID: 26509876
-
PEGylated Adenoviruses: From Mice to Monkeys.Viruses. 2010 Feb;2(2):468-502. doi: 10.3390/v2020468. Epub 2010 Feb 1. Viruses. 2010. PMID: 21994645 Free PMC article.
-
Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody.Br J Cancer. 1996 Mar;73(5):565-72. doi: 10.1038/bjc.1996.99. Br J Cancer. 1996. PMID: 8605088 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources